Description

CD90.2 is a 25-35 kD immunoglobulin superfamily member also known as Thy1.2. It is expressed on hematopoietic stem cells and neurons, all thymocytes, and peripheral T cells in Thy1.2 bearing mouse strains (Balb/c, CBA/J, C3H/He, C57BL/-, DBA, NZB/-). CD90.2 is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein involved in signal transduction. CD90.2 is involved in costimulation of lymphocyte proliferation and induction of hematopoietic stem cells differentiation. CD90.2 has been shown to interact with CD45. The 30-H12 antibody has been reported to induce Ca²⁺ flux in thymocytes and, in combination with antibody against the CD3/TCR complex, promote thymocyte apoptosis and inhibit CD3-mediated proliferative responses of mature T lymphocytes.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.03 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
2. Seaman WE. 1983. J. Immunol. 130:1713. (Deplete)
3. Nakashima I, et al. 1991. J. Immunol. 147:1153. (Costim)
4. Nakashima I, et al. 1993. J. Immunol. 151:3511. (Costim)
5. Ledbetter JA, et al. 1980. J. Exp. Med. 152:280. (IHC)
6. Hardy B, et al. 2005. Int. Immunol. 17:615.
7. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
8. Dyer KD, et al. 2007. J. Immunol. 179:1693. (FC) PubMed
9. Sungur CM, et al. 2013. PNAS. 110:7401. PubMed